Humoral Response to the HIV-1 Envelope V2 Region in a Thai Early Acute Infection Cohort.
CRF01_AE
HIV-1
RV217 prospective study
V2 region
acute infection
immune response
single genome amplification (SGA)
structural biology
surface plasmon resonance (SPR)
transmitted/founder (T/F) virus
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
19 04 2019
19 04 2019
Historique:
received:
22
03
2019
revised:
11
04
2019
accepted:
15
04
2019
entrez:
24
4
2019
pubmed:
24
4
2019
medline:
24
4
2019
Statut:
epublish
Résumé
Reduced risk of HIV-1 infection correlated with antibody responses to the envelope variable 1 and 2 regions in the RV144 vaccine trial. To understand the relationship between antibody responses, V2 sequence, and structure, plasma samples (n = 16) from an early acute HIV-1 infection cohort from Thailand infected with CRF01_AE strain were analyzed for binding to V2 peptides by surface plasmon resonance. Five participants with a range of V2 binding responses at week 24 post-infection were further analyzed against a set of four overlapping V2 peptides that were designed based on envelope single-genome amplification. Antibody responses that were relatively consistent over the four segments of the V2 region or a focused response to the C-strand (residues 165-186) of the V2 region were observed. Viral escape in the V2 region resulted in significantly reduced antibody binding. Structural modeling indicated that the C-strand and the sites of viral variation were highly accessible in the open conformation of the HIV-1 Env trimer. V2 residues, 165-186 are preferentially targeted during acute infection. Residues 169-184 were also preferentially targeted by the protective immune response in the RV144 trial, thus emphasizing the importance of these residues for vaccine design.
Identifiants
pubmed: 31010245
pii: cells8040365
doi: 10.3390/cells8040365
pmc: PMC6523213
pii:
doi:
Substances chimiques
AIDS Vaccines
0
Antibodies, Neutralizing
0
HIV Antibodies
0
HIV Envelope Protein gp120
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Commentaires et corrections
Type : ErratumIn
Jain, Swati [added]; Uritskiy, Gherman [added]; Rao, Venigalla B [added]
Déclaration de conflit d'intérêts
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Références
Immunity. 2013 Jan 24;38(1):176-86
pubmed: 23313589
Nature. 2012 Oct 18;490(7420):417-20
pubmed: 22960785
Nat Rev Immunol. 2010 Jul;10(7):527-35
pubmed: 20577269
J Virol. 2016 Mar 28;90(8):4005-4016
pubmed: 26842474
J Infect Dis. 2018 Oct 5;218(10):1541-1550
pubmed: 29893872
PLoS Pathog. 2017 Jul 31;13(7):e1006510
pubmed: 28759651
AIDS Res Hum Retroviruses. 2012 Nov;28(11):1444-57
pubmed: 23035746
PLoS One. 2018 Apr 26;13(4):e0194266
pubmed: 29698406
N Engl J Med. 2016 Jun 2;374(22):2120-30
pubmed: 27192360
J Virol. 2005 May;79(10):6528-31
pubmed: 15858037
J Infect Dis. 2018 Jul 13;218(4):633-644
pubmed: 29669026
PLoS One. 2014 Feb 04;9(2):e87572
pubmed: 24504509
PLoS One. 2015 Dec 01;10(12):e0143895
pubmed: 26625359
Immunity. 2017 May 16;46(5):777-791.e10
pubmed: 28514685
AIDS Res Hum Retroviruses. 2017 Aug;33(8):796-806
pubmed: 28401776
Cell Host Microbe. 2018 Oct 10;24(4):579-592.e4
pubmed: 30308160
Science. 2004 Mar 26;303(5666):2019-22
pubmed: 15044802
J Virol. 2008 Apr;82(8):3952-70
pubmed: 18256145
Nature. 2014 Oct 23;514(7523):455-61
pubmed: 25296255
Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):E7151-E7158
pubmed: 27799557
Science. 2013 Dec 20;342(6165):1484-90
pubmed: 24179160
N Engl J Med. 2012 Apr 5;366(14):1275-86
pubmed: 22475592
AIDS Res Hum Retroviruses. 2017 Jun;33(6):610-613
pubmed: 28073289
PLoS Pathog. 2016 Nov 16;12(11):e1005989
pubmed: 27851829
Nature. 2011 Nov 23;480(7377):336-43
pubmed: 22113616
Nat Med. 2018 Jun;24(6):847-856
pubmed: 29785023
N Engl J Med. 2009 Dec 3;361(23):2209-20
pubmed: 19843557
Nat Struct Mol Biol. 2015 Jul;22(7):522-31
pubmed: 26098315
Science. 2013 Dec 20;342(6165):1477-83
pubmed: 24179159
Nat Struct Mol Biol. 2013 Jul;20(7):804-13
pubmed: 23708607
Virology. 2012 Jun 5;427(2):198-207
pubmed: 22402248
J Virol. 2018 Jul 17;92(15):
pubmed: 29793957
Lancet Infect Dis. 2012 Jul;12(7):531-7
pubmed: 22652344
Immunity. 2017 Apr 18;46(4):690-702
pubmed: 28423342
Immunity. 2014 Dec 18;41(6):909-18
pubmed: 25526306
PLoS One. 2015 Mar 20;10(3):e0119608
pubmed: 25793890
PLoS One. 2017 Jan 20;12(1):e0170530
pubmed: 28107435
J Virol. 2014 Apr;88(8):4100-12
pubmed: 24478429
J Virol. 2014 Jul;88(14):7715-26
pubmed: 24807721
Nat Commun. 2018 Oct 26;9(1):4489
pubmed: 30367034
Nat Struct Mol Biol. 2016 Jan;23(1):81-90
pubmed: 26689967
Elife. 2017 May 26;6:
pubmed: 28548638
J Virol. 2006 Oct;80(19):9586-98
pubmed: 16973562